Korro Bio, Inc. (NASDAQ:KRRO) to Post Q3 2024 Earnings of ($2.79) Per Share, William Blair Forecasts

Korro Bio, Inc. (NASDAQ:KRRO) – Investment analysts at William Blair issued their Q3 2024 earnings estimates for shares of Korro Bio in a research report issued on Monday, September 16th. William Blair analyst M. Minter anticipates that the company will post earnings per share of ($2.79) for the quarter. William Blair has a “Outperform” rating and a $180.00 price target on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($10.29) per share. William Blair also issued estimates for Korro Bio’s Q4 2024 earnings at ($2.89) EPS, FY2024 earnings at ($10.56) EPS, Q1 2025 earnings at ($2.95) EPS, Q2 2025 earnings at ($2.99) EPS, Q3 2025 earnings at ($3.04) EPS, Q4 2025 earnings at ($3.09) EPS and FY2025 earnings at ($12.07) EPS.

A number of other research firms have also recently issued reports on KRRO. Royal Bank of Canada cut their target price on shares of Korro Bio from $105.00 to $95.00 and set an “outperform” rating for the company in a research note on Wednesday, August 14th. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Korro Bio in a report on Tuesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $135.00.

Korro Bio Stock Down 1.4 %

KRRO stock opened at $36.73 on Thursday. The company has a fifty day moving average price of $43.88 and a two-hundred day moving average price of $51.40. Korro Bio has a one year low of $9.15 and a one year high of $97.91.

Korro Bio (NASDAQ:KRRO) last posted its earnings results on Tuesday, August 13th. The company reported ($2.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.04).

Hedge Funds Weigh In On Korro Bio

Hedge funds have recently bought and sold shares of the business. Atlas Venture Life Science Advisors LLC bought a new position in shares of Korro Bio during the fourth quarter worth approximately $53,648,000. Monashee Investment Management LLC bought a new position in Korro Bio during the 4th quarter worth $4,352,000. 72 Investment Holdings LLC acquired a new position in Korro Bio in the 4th quarter valued at $13,269,000. Eventide Asset Management LLC bought a new stake in shares of Korro Bio during the 4th quarter valued at $26,185,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Korro Bio during the 2nd quarter worth $649,000. 13.18% of the stock is owned by institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).